1. Sutherland DE, Gruessner AC, Gruessner RW. Pancreas transplantation: a review. Transplant Proc. 1998. 30:1940–1943.
2. American Diabetes Association. Pancreas transplantation for patients with type 1 diabetes. Diabetes Care. 2000. 23:suppl 1. S85.
3. Panza JL, Wagner WR, Rilo HLR, Rao RH, Beckman EJ, Russell AJ. Treatment of rat pancreatic islets with reactive PEG. Biomaterials. 2000. 21:1155–1164.
4. Aomatsu Y, Nakajima Y, Ohyama T, Kin T, Kanehiro H, Hisanaga M, Ko S, Nagao M, Tatekawa Y, Sho M, Ikeda N, Kanokogi H, Kobayashi T, Urizono Y, Yamada T, Shibaji T, Kanamura T, Ogawa S, Iwata H, Nakano H. Efficacy of agarose/polystyrene sulfonic acid microencapsulation for islet xenotransplantation. Transplant Proc. 2000. 32:1071–1072.
5. Liu EH, Herold KC. Transplantation of the Islets of Langerhans. New Hope for Treatment of Type 1 Diabetes Mellitus. Trends Endocrinol Metab. 2000. 11:379–382.
6. Zwillich T. Diabetes research. Islet transplants not yet ready for prime time. Science. 2000. 289:531–533.
7. Yamasaki K, Sasaki T, Nemoto M, Eto Y, Tajima N. Differentiation-induced insulin secretion from nonendocrine cells with engineered human proinsulin cDNA. Biochem Biophys Res Commun. 1999. 265:361–365.
8. Gros L, Riu E, Montoliu L, Ontiveros M, Lebrigand L, Bosch F. Insulin production by engineered muscle cells. Hum Gene Ther. 1999. 10:1207–1217.
9. Arcelloni C, Falqui L, Martinenghi S, Stabilini A, Pontiroli AE, Paroni R. Processing and release of human proinsulin-cleavage products into culture media by different engineered non-endocrine cells: a specific assessment by capillary electrophoresis. J Endocrinol. 2000. 166:437–445.
10. Scougall KT, Shaw JA. Tetracycline-regulated secretion of human insulin in transfected primary myoblasts. Biochem Biophys Res Commun. 2003. 304:167–175.
11. Shaw JA, Delday MI, Hart AW, Docherty HM, Maltin CA, Docherty K. Secretion of bioactive human insulin following plasmid-mediated gene transfer to non-neuroendocrine cell lines, primary cultures and rat skeletal muscle in vivo. J Endocrinol. 2002. 172:653–672.
12. Simonson GD, Groskreutz DJ, Gorman CM, MacDonald MJ. Synthesis and processing of genetically modified human proinsulin by rat myoblast primary cultures. Hum Gene Ther. 1996. 7:71–78.
13. Wilson MO, Scougall KT, Ratanamart J, McIntyre EA, Shaw JA. Tetracycline-regulated secretion of human (pro) insulin following plasmid-mediated transfection of human muscle. J Mol Endocrinol. 2005. 34:391–403.
14. Clark SA, Quaade C, Constandy H, Hansen P, Halban P, Ferber S, Newgard CB, Normington K. Novel insulinoma cell lines produced by iterative engineering of GLUT2, glucokinase, and human insulin expression. Diabetes. 1997. 46:958–967.
15. Yaffe D, Saxel O. Serial passaging and differentiation of myogenic cells isolated from dystrophic mouse muscle. Nature. 1977. 270:725–727.
16. Mitanchez D, Doiron B, Chen R, Kahn A. Glucose-stimulated genes and prospects of gene therapy for type I diabetes. Endocr Rev. 1997. 18:520–540.
17. Vollenweider F, Irminger JC, Gross DJ, Villa-Komaroff L, Halban PA. Processing of proinsulin by transfected hepatoma (FAO) cells. J Biol Chem. 1992. 267:14629–14636.
18. Barr E, Leiden JM. Systemic delivery of recombinant proteins by genetically modified myoblasts. Science. 1991. 254:1507–1509.
19. Dhawan J, Pan LC, Pavlath GK, Travis MA, Lanctot AM, Blau HM. Systemic delivery of human growth hormone by injection of genetically engineered myoblasts. Science. 1991. 254:1509–1512.